Investor's Business Daily on MSN40m
Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy Sales
Gilead Sciences easily beat third-quarter forecasts late Wednesday, and raised its outlook in a move that could bolster ...
Hosted on MSN21m
'This Is A New Teva,' Says CEO. But Investors Don't Seem To Believe.
Teva stock plunged Wednesday — sacrificing an earlier breakout — despite beating third-quarter expectations and raising its guidance.